Cellectricon and Fluxion said they will ask the US District Court for the Northern District of California to dismiss all claims that Cellectricon brought against Fluxion involving US Patent Nos. 7,390,650; 7,470,518; and 7,563,614.
"Resolution of this lawsuit allows us to focus on providing innovative and enabling products and discovery services for drug discovery and life science research globally," Cellectricon CEO David Burns said in a statement.
Jeff Jensen, CEO of Fluxion, added, "We believe it is a win-win for both companies, and will benefit our customers as we can now focus all of our attention on developing and providing solutions that continue to deliver maximum benefit to them."
When Cellectricon sued Fluxion, it alleged infringement of four patents — the three covered by today's settlement announcement, as well as US Patent No. 5,376,252, a patent held by Gyros but licensed to Cellectricon. The firms settled the dispute over the '252 patent late last year.
The patents covered microfluidic technology used in Cellectricon's ion channel drug screening solution, the Dynaflow HT System. Cellectricon had claimed Fluxion's IonFlux automated patch clamp system infringed the patents, as GenomeWeb Daily News' sister publication BioArray News previously reported.
Cellectricon, based on MöIndal, Sweden provides cellular screening technologies. Fluxion, headquartered in South San Francisco, Calif., provides analytical instruments for functional cell-based assays.
Cellectricon and Fluxion Biosciences announced today they have settled a legal dispute dating back to 2009 in which Fluxion was accused of patent infringement.